Immunovant’s
Developing transformative therapies for autoimmune diseases with the goal of redefining outcomes for those affected by these conditions. Learn more
Launch date
Employees
Market cap
AUD6.7b
Enterprise valuation
AUD5.8b (Public information from Sep 2024)
Share price
$29.59 IMVT
New York City New York (HQ)
Authorizing premium user...